Par Pharmaceutical Companies, Inc.

• Why Does Billionaire Thomas Steyer’s Farallon Love This Pharmaceutical Company?

  By Meena Krishnamsetty - October 4, 2012 | Tickers: HZNP, MACK, PRX, PRGO, THLD

  In a 13G filing last week, billionaire fund manager Thomas Steyer of Farallon Capital Management announced that his firm now had 5.4% ownership of Horizon Pharma (NASDAQ: HZNP) after buying almost 1.9 million shares. Steyer founded Farallon in 1986, and previously worked for Goldman Sachs and Morgan Stanley.

  The Farallon news came in conjunction with other recent reports that notable pharmaceutical investors Tang Capital and Sutter Hill Ventures more »

• Leon Cooperman’s Diamond in the Rough

  By Ryan Guenette - July 24, 2012 | Tickers: ACT, MYL, PRX, TEVA

  Yesterday at the Delivering Alpha Conference Leon Cooperman presented on the “best ideas” panel his top stock picks for 2012. When asked to present his one best idea for 2012, Leon Cooperman said he could not distinguish between his top picks because choosing one was like picking between his children. Leon Cooperman, The Omega Advisors CEO, was able to distinctly say that putting money in treasuries is a waste of more »

• J.P. Morgan Healthcare Conference Schedule: Day One

  By Brandy Betz - January 8, 2012 | Tickers: ARAY, ACOR, A, ALGN, AMRN, AMGN, AMLN, ARTC, BIIB, BMRN, BRKR, CFN, CTRX, CELG, CNC, COV, DNDN, XRAY, EW, ENDP, EPOC, ESRX, GHDX, GILD, HLS, HTWR, HMSY, HGSI, IDXX, IPXL, INCY, IRWD, MCK, MRX, MDT, MR, MOH, MYL, NVS, ONXX, PRX, PRGO, QSII, REGN, RMD, RIGL, SGEN, ST, SIAL, THC, MDCO, THOR, VRTX, VVUS, WAT, WMGI, ZLTQ

  The 30th Annual J.P. Morgan Healthcare Conference kicks off with a full day of presentations from companies that range from global pharmaceutical leaders to small cap novel pharmaceutical developers and health technology manufacturers. The majority of the presentations will be available through live webcasts with archived replay offered later in the day.

  I will be following (and covering) the novel therapeutic companies that have caught my eye. VIVUS (NASDAQ: VVUSmore »)